Menu
Menu
Under the Articles of Association, the Company’s Board has three (3) to eight (8) members with no more than two (2) alternates. Board members and alternates are elected at the AGM. The Board’s assignment is valid until the end of the next AGM, scheduled for the 24th of May 2022. Management and all Board members can be reached through the Company’s headquarters at Mårtenstorget 5, SE-223 51 Lund, Sweden. The Board’s work is governed by the Companies Act, the Articles of Association and the Rules of Procedure adopted by the Board.
Number of shares: 0
Number of warrants: 0
Dependent of the company, independent of larger shareholders.
Master’s degree in Sports and Public Health from Karolinska Institutet, IMD Business School Strategy and Management Education, and INSEAD International Management Education.
International leader with over 30 years of experience in the Life Science industry, including 20 years as CEO of Life Science companies such as AstraZeneca Hungary, Schering-Plough and Organon Biosciences Sweden, AutomationsPartner Sweden, and Fürst Medicinskt Laboratorium Filial Sweden. Extensive industry and technical knowledge in sales, marketing, market access, and management. Experienced entrepreneur with expertise in diagnostics, automation, digital pathology, global marketing, acquisitions, organic growth, and implementation of efficiency measures.
Number of shares: 25 000
Number of warrants: 0
Independent of the company’s major shareholders, the company and its management.
Microbiologist, Uppsala University, and has nearly 40 years of experience in the life science industry. In the field of in vitro diagnostics, she has worked on bacterial and viral diagnostic development as well as the development of instruments and reagents, including antibody-based reagents, at Pharmacia Diagnostics. In the field of medical technology, she has worked at Arjo AB (publ) on product development, documentation systems, quality control, and process control of CAPA (corrective and preventive actions) as well as deviation management. She has previously served as a board member of Arjo AB (publ) and Svenskt Projektforum.
Number of shares: 0
Number of warrants: 0
Independent of the company’s major shareholders, the company and its management.
Professor of Surgery at Lund University since 2000. Extensive clinical experience and clinical as well as translational research. Author of over 500 articles in peer-reviewed journals. Supervised around 30 completed doctoral students in the fields of cancer, systemic inflammation, organ failure, and intestinal function.
Other current positions: Professor of Surgery, Lund University. CEO and board member of Foresight Pharma AB. Chairman of the board at Reccan Diagnostics AB. Board member of Nordic Biotechnology AB, Aqilion AB, and Nordic Oncology in Lund AB.
Number of shares: 120 000
Number of warrants: 0
Independent of the company, dependent of larger shareholders.
Bachelor of Medicine, Karolinska Institutet, Bachelor of Business Administration and Master’s degree, Stockholm School of Economics.
Ulf Bladin has previously held positions such as General Manager, Vice President for the EMEA region at Hycor Biomedical, Vice President of Commercial Operations Europe at Thermo Fisher Scientific Immuno Diagnostics Division, and Vice President with global responsibility for Marketing, Health Economy, Corporate Communications, Scientific & Regulatory Affairs at Phadia AB. Ulf Bladin has also held senior commercial positions in the pharmaceutical industry at Pfizer and Merck Sharp & Dhome.
Other current positions: CEO and board member of Prolight Diagnostics AB (publ.), SPCIN AB, and UB Management Invest AB.
Number of shares: 2 100 000
Number of warrants: 0
Dependent of the company, independent of larger shareholders.
Professor of Physics at Lund University until 2016. Since 2016, Director of Biophotonics (leading a team of 40 researchers) at Tyndall National Institute, Ireland. Received the Erna Ebeling Prize from the Swedish Society for Medical Engineering and Physics in 2003. Pre-candidate for the appointment of the professorship in Biomedical Physics at the Royal Institute of Technology, Stockholm, in 1996. Co-author of over 200 articles in peer-reviewed journals.
Other current positions: Director of Biophotonics at Tyndall National Institute, Ireland. Deputy Director of the Photonics Centre IPIC, Cork, Ireland. Professor of Physics at University College Cork, Ireland. Chairman of the Board of NanoEcho AB (publ).
Number of shares: 400 000
Number of warrants: 1 000 000
Education: Degree Certificate in Marketing Management at IHM Business School, Stockholm.
Background: Mattias Lundin has extensive experience driving growth globally with intelligent and new technology and is an international leader with 18 years of experience in the healthcare industry. He most recently came from a position as Global Sales Manager for the Swedish, world-leading medical technology company CellaVision. He has also worked as Nordic CEO, CEO of the Netherlands and VP of Commercial mature markets at ArjoHuntleigh (now Arjo) within the Getinge Group.
Other current positions: Chairman of the Board of Decon Products Holding AB. Board member of Neola Medical AB.
Number of shares: 167 500
Number of warrants: 0
Education: Master’s degree in Mechanical Engineering, Lund University.
Background: Lars Lindgren has 35 years of experience and extensive expertise in the development of medical equipment, working in both startups and multinational companies as a Project Manager and Director of Research & Development.
Number of shares: 109 707
Number of warrants: 0
Education: Master of Science in Electrical Engineering, Lund University.
Background: Andreas Johansson has over 20 years of experience in product development and system design, encompassing both hardware and software. His previous work includes algorithm development for handwriting recognition, consultancy in embedded systems, and most recently, serving as a systems engineer at Flatfrog AB.
Number of shares: 230 125
Number of warrants: 0
Education: Bachelor in Business Administration and Economics, Lund University.
Background: Henrik Ljung has a background as a certified auditor and extensive experience as a CFO, including positions at Cerdo Bankpartner Aktiebolag, Acconeer AB, Ballingslöv AB, AB Sardus, and Malmöhus Invest AB.
Other current positions: CFO of SpectraCure AB, Prolight Diagnostics AB, NanoEcho AB, and Carbiotix AB. Board member of Ljung och Winbladh AB.
Number of shares: 0
Number of warrants: 0
Education: Master of Science in Chemical Engineering, Lund University.
Background: Anna Linde has over 20 years of experience in quality management systems, project management, and technical product management for medical devices and in vitro diagnostics in the industry. She has worked with products from the research phase, through the design/development and launch phase, to product maintenance in both startups and international companies. She has previously worked for BrainCool, Immunovia, Baxter, and Gambro.
The Nomination Committee for the 2023 Annual General Meeting of Lumito AB (publ) consists of the following individuals:
Proposals can be submitted by email to the following address: valberedning@lumito.se
Articles of association
We have telephone hours on weekdays between 08:00 and 14:30. Closed for lunch 12-13.
Phone: +46(0)10-204 00 15
Mail: info@lumito.se
Lumito AB (publ)
Mårtenstorget 5, 223 51, Lund